European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Exploring the origins of frequent tau-PET signal in vermal and adjacent regions","authors":"Agnes Kling, Julia Kusche-Palenga, Carla Palleis, Alexander Jäck, Alexander M. Bernhardt, Lukas Frontzkowski, Sebastian N. Roemer, Luna Slemann, Mirlind Zaganjori, Maximilian Scheifele, Lars Paeger, Gérard N. Bischof, Thilo van Eimeren, Alexander Drzezga, Osama Sabri, Michael Rullmann, Henryk Barthel, Johannes Levin, Jochen Herms, Nicolai Franzmeier, Günter Höglinger, Sigrun Roeber, Matthias Brendel, Johannes Gnörich","doi":"10.1007/s00259-025-07199-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07199-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Off-target binding remains a significant challenge in tau-PET neuroimaging. While off-targets including monoamine oxidase enzymes and neuromelanin-containing cells have been identified, recent studies indicated a relevant binding of novel tau tracers to melanin-containing structures. To date, little is known about the effect of melanocytes in the meninges on tracer signals in brain PET data. Thus, we aimed to identify the target structure causal for the frequently observed [¹⁸F]PI-2620 PET signal in the vermis and adjacent cerebellar regions.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>274 participants underwent dynamic [¹⁸F]PI-2620 tau-PET: 3/4R-tauopathies (n = 85), 4R-tauopathies (n = 147), tau-negative disease controls (n = 24), and healthy controls (n = 18). Standardized uptake value ratio (SUVR) and kinetic parameters including the distribution volume ratio (DVR), tracer clearance (k2) and relative perfusion (R1), were compared among the cohorts and sexes using the Automated Anatomical Labelling (AAL) atlas. Age and p-Tau levels in cerebrospinal fluid (CSF) were assessed for their relationship with vermal tau-PET signal. Furthermore, we combined autoradiographic and histochemical experiments on post-mortem brain tissue of deceased patients (n = 9).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Male participants revealed higher mean vermal [¹⁸F]PI-2620 DVR (0.95 ± 0.13; vs. females 0.88 ± 0.10, p &lt; 0.0001). Sex-related differences were most pronounced in the 3/4R-tauopathy cohort (p &lt; 0.0001). Mean SUVR_Ver/Cbl, k2 and correlation analyses of kinetic parameters did not differ among groups. Histological assessments revealed co-localization of leptomeningeal pigmented cells with strong autoradiography signal spots within the vermal fissures. Tau-related autoradiography signals, age or p-Tau levels did not correlate significantly with tau-PET signals. Iron deposits did not cause relevant autoradiography signals in the vermis.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Leptomeningeal melanocytes are the primary target structure for [¹⁸F]PI-2620 PET binding in anterior vermis, whereas iron and tau deposits do not contribute significantly.\u0000</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"10 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143640554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"131I SPECT/CT provides prognostic information in patients with differentiated thyroid cancer","authors":"Marieke Heinrich, Elias Blickle, Philipp E. Hartrampf, Natalie Hasenauer, Aleksander Kosmala, Alexander Kerscher, Nicolas Schlegel, Frederik A. Verburg, Andreas K. Buck, Kerstin Michalski","doi":"10.1007/s00259-025-07187-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07187-1","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>The aim of this study is to investigate the impact of lymph node metastases (LNM) detected on cervical ¹³¹I single photon emission computed tomography/computed tomography (SPECT/CT) after the first radioiodine therapy (RAI) on complete response (CR) and progression-free survival (PFS) in patients with differentiated thyroid cancer (DTC).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This retrospective study included 942 DTC patients who underwent cervical ¹³¹I SPECT/CT after their first RAI. LNM were categorized based on CT (enlarged ≥ 1 cm, small &lt; 1 cm) and ¹³¹I uptake. CR and PFS were analysed using Kaplan–Meier curves and Cox regression.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Patients with no LNM had a shorter median time to CR (9.4 months) than those with LNM (44 months, HR 2.2; <i>p</i> &lt; 0.01) and a lower risk of progression (median PFS not reached, HR 0.46; <i>p</i> &lt; 0.01). Among patients with LNM, those with enlarged ¹³¹I negative LNM had the longest time to CR (24 months, HR 0.36; <i>p</i> &lt; 0.01). Patients with small LNM had a PFS similar to patients without LNM (median PFS not reached, HR 1.22; <i>p</i> = 0.54). Reoperation after first RAI (13.5 months) led to earlier CR than second RAI (median not reached) in patients with enlarged LNM. For small LNM, second RAI was associated with longer PFS than reoperation (38.4 months vs. not reached, HR 4.0; <i>p</i> = 0.02).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Patients without LNM on post-therapy ¹³¹I SPECT/CT have better chances for early CR and longer PFS. Patients with LNM benefit from early reoperations but treatment strategies should be tailored based on LNM characteristics.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"92 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial blood flow reference values for 13N-ammonia PET myocardial perfusion imaging in patients without flow-limiting coronary artery disease","authors":"Rita Pingree, Susanne Markendorf, Dimitrios Moysidis, Christoph Ryffel, Magdalena Stuetz, Raffael Ghenzi, Marko Gajic, Dominik C. Benz, Aju P. Pazhenkottil, Andreas A. Giannopoulos, Philipp A. Kaufmann, Simon Winther, Ronny R. Buechel","doi":"10.1007/s00259-025-07196-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07196-0","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To determine the most important patient factors influencing quantitative MBF and to report the lower (LRL) and upper (URL) reference limits for 13N-ammonia positron emission tomography (PET) myocardial perfusion imaging (MPI).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Patients who underwent 13N-ammonia PET-MPI were screened, and those with evidence of myocardial ischemia or scar, known cardiomyopathy, impaired left ventricular function, non-response to vasodilators, and those who underwent a stress-rest protocol were excluded. Multiple linear regression analyses were performed to identify independent predictors of rest MBF (rMBF), stress MBF (sMBF), and myocardial flow reserve (MFR), and predictor importance was calculated. Finally, median, LRL, and URL for rMBF, sMBF, and MFR were calculated based on the presence of predictors.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Among 784 patients with a median coronary artery calcium score (CACS) of 69, median rMBF was 0.75mL∙min^− 1∙g^− 1 (LRL = 0.49 mL∙min^− 1∙g^− 1; URL = 1.33 mL∙min^− 1∙g^− 1), median sMBF was 2.41mL∙min^− 1∙g^− 1 (LRL = 1.42 mL∙min^− 1∙g^− 1; URL = 3.73 mL∙min^− 1∙g^− 1), and median MFR was 3.09 (LRL = 2.11; URL = 4.65). The body mass index (BMI) was the single most important independent predictor of rMBF, sMBF, and MFR (predictor importance of 72%, 87%, and 41%, respectively; standardized β=-0.434, -0.566 and − 0.174, respectively). Additional predictors were sex and hypertension for rMBF, sex for sMBF, and hypertension and CACS for MFR.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>In patients without flow-limiting CAD, MBF is strongly influenced by the patient’s habitus, whereby median and reference limits for sMBF and rMBF decrease with increasing BMI. Consequently, MFR exhibits stable lower reference limits across a wide range of BMI and may be considered the most robust quantitative parameter derived from 13N-ammonia PET-MPI.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"213 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"68Ga-Trivehexin PET/CT uptake in malignant and fibrotic lung tissue: refining diagnostic applications","authors":"Serkan Kuyumcu, Dilara Denizmen Zorba, Zeynep Gözde Özkan","doi":"10.1007/s00259-025-07193-3","DOIUrl":"https://doi.org/10.1007/s00259-025-07193-3","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"87 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CT-free attenuation and Monte-Carlo based scatter correction-guided quantitative 90Y-SPECT imaging for improved dose calculation using deep learning","authors":"Zahra Mansouri, Yazdan Salimi, Nicola Bianchetto Wolf, Ismini Mainta, Habib Zaidi","doi":"10.1007/s00259-025-07191-5","DOIUrl":"https://doi.org/10.1007/s00259-025-07191-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>This work aimed to develop deep learning (DL) models for CT-free attenuation and Monte Carlo-based scatter correction (AC, SC) in quantitative ⁹⁰Y SPECT imaging for improved dose calculation.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Data of 190 patients who underwent ⁹⁰Y selective internal radiation therapy (SIRT) with glass microspheres was studied. Voxel-level dosimetry was performed on uncorrected and corrected SPECT images using the local energy deposition method. Three deep learning models were trained individually for AC, SC, and joint ASC using a modified 3D shifted-window UNet Transformer (Swin UNETR) architecture. Corrected and unorrected dose maps served as reference and as inputs, respectively. The data was split into train set (~ 80%) and unseen test set (~ 20%). Training was conducted in a five-fold cross-validation scheme. The trained models were tested on the unseen test set. The model’s performance was thoroughly evaluated by comparing organ- and voxel-level dosimetry results between the reference and DL-generated dose maps on the unseen test dataset. The voxel and organ-level evaluations also included Gamma analysis with three different distances to agreement (DTA (mm)) and dose difference (DD (%)) criteria to explore suitable criteria in SIRT dosimetry using SPECT.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The average ± SD of the voxel-level quantitative metrics for AC task, are mean error (ME (Gy)): -0.026 ± 0.06, structural similarity index (SSIM (%)): 99.5 ± 0.25, and peak signal to noise ratio (PSNR (dB)): 47.28 ± 3.31. These values for SC task are − 0.014 ± 0.05, 99.88 ± 0.099, 55.9 ± 4, respectively. For ASC task, these values are as follows: -0.04 ± 0.06, 99.57 ± 0.33, 47.97 ± 3.6, respectively. The results of voxel level gamma evaluations with three different criteria, namely “DTA: 4.79, DD: 1%”, “DTA:10 mm, DD: 5%”, and “DTA: 15 mm, DD:10%” were around 98%. The mean absolute error (MAE (Gy)) for tumor and whole normal liver across tasks are as follows: 7.22 ± 5.9 and 1.09 ± 0.86 for AC, 8 ± 9.3 and 0.9 ± 0.8 for SC, and 11.8 ± 12.02 and 1.3 ± 0.98 for ASC, respectively.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>We developed multiple models for three different clinically scenarios, namely AC, SC, and ASC using the patient-specific Monte Carlo scatter corrected and CT-based attenuation corrected images. These task-specific models could be beneficial to perform the essential corrections where the CT images are either not available or not reliable due to misalignment, after training with a larger dataset.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"8 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of deep learning denoising on kinetic modelling for low-dose dynamic PET: application to single- and dual-tracer imaging protocols","authors":"Florence M. Muller, Elizabeth J. Li, Margaret E. Daube-Witherspoon, Austin R. Pantel, Corinde E. Wiers, Jacob G. Dubroff, Christian Vanhove, Stefaan Vandenberghe, Joel S. Karp","doi":"10.1007/s00259-025-07182-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07182-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Long-axial field-of-view PET scanners capture multi-organ tracer distribution with high sensitivity, enabling lower dose dynamic protocols and dual-tracer imaging for comprehensive disease characterization. However, reducing dose may compromise data quality and time-activity curve (TAC) fitting, leading to higher bias in kinetic parameters. Parametric imaging poses further challenges due to noise amplification in voxel-based modelling. We explore the potential of deep learning denoising (DL-DN) to improve quantification for low-dose dynamic PET.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Using 16 [¹⁸F]FDG PET studies from the PennPET Explorer, we trained a DL framework on 10-min images from late-phase uptake (static data) that were sub-sampled from 1/2 to 1/300 of the counts. This model was used to denoise early-to-late dynamic frame images. Its impact on quantification was evaluated using compartmental modelling and voxel-based graphical analysis for parametric imaging for single- and dual-tracer dynamic studies with [¹⁸F]FDG and [¹⁸F]FGln at original (injected) and reduced (sub-sampled) doses. Quantification differences were evaluated for the area under the curve of TACs, K_i for [¹⁸F]FDG and V_T for [¹⁸F]FGln, and parametric images.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>DL-DN consistently improved image quality across all dynamic frames, systematically enhancing TAC consistency and reducing tissue-dependent bias and variability in K_i and V_T down to 40 MBq doses. DL-DN preserved tumor heterogeneity in Logan V_T images and delineation of high-flux regions in Patlak K_i maps. In a /[¹⁸F]FDG dual-tracer study, bias trends aligned with single-tracer results but showed reduced accuracy for [¹⁸F]FGln in breast lesions at very low doses (4 MBq).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This study demonstrates that applying DL-DN trained on static [¹⁸F]FDG PET images to dynamic [¹⁸F]FDG and [¹⁸F]FGln PET can permit significantly reduced doses, preserving accurate FDG K_i and FGln V_T measurements, and enhancing parametric image quality. DL-DN shows promise for improving dynamic PET quantification at reduced doses, including novel dual-tracer studies.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"54 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143599333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer","authors":"Bastiaan M. Privé, Tim M. Govers, Bas Israël, Marcel J. R. Janssen, Bart J. R. Timmermans, Steffie M. B. Peters, Michel de Groot, Patrik Zámecnik, Stan R. W. Wijn, Alexander Hoepping, J. P. Michiel Sedelaar, Jelle O. Barentsz, Inge M. van Oort, Maarten de Rooij, James Nagarajah","doi":"10.1007/s00259-025-07190-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07190-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is currently under evaluation for detecting clinically significant prostate cancer. The PSMA-PET/CT may complement the current standard diagnostic pathway for prostate cancer, which includes prostate-specific antigen (PSA) testing and multiparametric magnetic resonance imaging (mpMRI). This study evaluated the cost-effectiveness and quality of life impact of incorporating PSMA-PET/CT into this diagnostic algorithm.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A life-time decision model compared the current standard of care of a MRI driven diagnostic pathway, where men undergo prostate biopsy in case of a Prostate Imaging Reporting and Data System (PI-RADS) scores 3–5, to a strategy incorporating PSMA-PET/CT to potentially avoid unnecessary biopsies. Long-term quality-adjusted life years (QALY) and healthcare costs were calculated for each approach.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In PI-RADS 3 lesions, PSMA-PET/CT improved the per-patient QALY by 0.002 and was borderline cost-effective, with an increased cost of €170-€186 per patient and an incremental cost-effectiveness ratio (ICER) of €56,700-€93,212 per QALY. In PI-RADS 1–2, additional biopsies and over-detection of low-risk prostate cancers led to a per-patient QALY decrease of 0.001 points, a cost increase of €416-€429 per patient and was thus not cost-effective.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The addition of PSMA-PET/CT to MRI in patients with equivocal MRI findings appears to be borderline cost-effective due to biopsy avoidance and a reduced detection of indolent, low-risk tumors. In men with a negative MRI, adding a PSMA-PET/CT does not seem to be cost-effective due to a higher number of unnecessary biopsies and only minor improvement in the detection of clinically significant prostate cancer.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"54 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143599605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alternative treatment for recurrent keloids: initial clinical experience with Rhenium-188 using a specialized device","authors":"Kgomotso M. G. Mokoala, Linda Nonjola, Thabiso Moeng, Cecilia Corbett, Martin Magwaza, Gerhard Dahlhoff, Shannon Brown, Nicholas Vetter, Mariza Vorster, Mike Machaba Sathekge","doi":"10.1007/s00259-025-07184-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07184-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>Keloids have proved challenging to manage with various therapies providing variable success rates and recurrences. Alternative therapies or a multimodal approach is often necessary to ensure complete eradication and prevent recurrence. The use of radioactive creams or patches embedded with Holmium-166, Phosphorus-32 for superficial skin lesions has been documented to be safe and effective. The use of Rhenium-188 has proved effective in non-melanoma skin cancers. We report on the initial experience with Rhenium-188 SCT in the treatment of recurrent keloid lesions.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Patients with recurrent keloid lesions were recruited for therapy with Rhenium-188. These patients had failed most forms of therapy including surgery, intralesional steroids and radiation therapy. Treatment with ¹⁸⁸Re via a specialized unit (Rhenium SCT -Oncobeta) was applied onto the keloid lesion. A personalized treatment time was calculated for every patient. Topical ¹⁸⁸Rhenium delivered as a jelly like matrix containing an insoluble dirhenium-heptasulfide was applied to every target lesion in a single session. The goal is to deliver 30 Gy to the deepest part of the lesion per session (3 mm). Patients were followed up at 2 weeks, 1, 3, 6 and 12 months for side effects as well as clinical and cosmetic outcomes.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 58 lesions were treated. Majority of the lesions were in the head and neck region. The smallest area for treatment was 0.25cm² and the largest area treated was 46.25cm². With the exception of four patients (2 sessions to the same lesion), all the other patients received a single session of therapy. The mean activity administered was 256,7MBq (range: 35MBq– 663,50MBq). The treatment time averaged 350.89 min (range: 85–1304 min). There was complete response in 72% of the lesions. Hypopigmentation was the commonest expected long term side effect. After a median follow-up period of 37 months (range: 7–53), there was a 7% recurrence rate.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Treatment with ¹⁸⁸Re is a great alternative in patients with keloids that have had minimal success with other therapies. The use of the specialized applicator system provides great flexibility, reduced morbidity and great results that are comparable to other therapies.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial number</h3><p>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"33 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143599500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-Head comparison of [18F]FES and [18F]FDG PET/CT in breast cancer patients: has a new era come?","authors":"Priscilla Guglielmo, Rosario Mazzola, Shadya Sara Darwish, Francesco Valenti, Tommaso Martino De Pas, Lucia Setti, Manuela Bonacina, Massimo Maria Grassi, Laura Evangelista","doi":"10.1007/s00259-025-07186-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07186-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This review systematically compared, in a head-to-head manner, the diagnostic and prognostic performance of [¹⁸F]FDG and [¹⁸F]FES PET/CT in breast cancer (BC) patients.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A systematic literature search was conducted in PubMed, Scopus, and Web of Science databases up to January 2025, without temporal limitations or restrictions on the number of patients in the included studies, to identify relevant articles comparing the diagnostic value of [¹⁸F]FDG and [¹⁸F]FES PET in BC patients. Selected imaging studies were analyzed using a modified version of the Critical Appraisal Skills Programme checklist dedicated to systematic reviews.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 20 papers were evaluated. Based on the CASP analysis, the quality of the study was variable. Totally, 806 patients affected by BC underwent both [¹⁸F]FDG and [¹⁸F]FES PET. Different setting of disease were considered, such as staging/diagnostic and prognostic value. In the initial staging of disease, [¹⁸F]FES PET/CT seemed to be more accurate than [¹⁸F]FDG. In the prognostic field, [¹⁸F]FES expression was a positive factor for the better prognosis, in particular when the amount of [¹⁸F]FDG uptake was low. [¹⁸F]FES seemed to be promising as a molecular agent in patients affected by invasive lobular BC.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>These findings underscore the potential of [¹⁸F]FES as a complementary imaging biomarker to [¹⁸F]FDG, advocating for further studies to standardize PET metrics and refine their combined clinical utility.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"14 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143590279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of a single-day protocol for SPECT and PET assessment of dopamine transporter availability, cardiac innervation and metabolic patterns in patients with movement disorders","authors":"Maximilian Scheifele, Johannes Gnörich, Elisabeth Schröder, Sophie C. Kunte, Zachary Ells, Johannes Hagen, Sabrina Katzdobler, Carla Palleis, Alexander Bernhardt, Alexander Jäck, Nicolai Franzmeier, Maximilian Fischer, Johannes Levin, Günter U. Höglinger, Rudolf A. Werner, Matthias Brendel","doi":"10.1007/s00259-025-07188-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07188-0","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Due to new advances in molecular and imaging biomarkers, a biological classification of Parkinson’s disease (PD) called SyNeurGe (Hoglinger et al. Lancet Neurol 2024;23:191-204) has been proposed for research use recently. [¹²³I]ioflupane dopamine transporter single-photon-emission-computed tomography (DaT-SPECT) and cardiac [¹²³I]meta-iodobenzylguanidine (MIBG) scintigraphy are included in this biological classification scheme together with 2-[¹⁸F]fluoro-2-deoxy-D-glucose (FDG-PET) as central imaging biomarkers for the assessment of dopaminergic function, cardiac sympathetic denervation, and metabolic patterns in brain. In order to facilitate this prospectively high imaging demand and optimize diagnostic workup in PD we propose a single-day protocol.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>First, we excluded relevant binding of MIBG in the brain as well as DaT in the heart by acquisition of brain scans in patients that received MIBG as well as by acquisition of chest scans in patients that received DaT. Then, we performed a single-day protocol including DaT-SPECT and cardiac MIBG scintigraphy in ten patients with clinically suspected α-synucleinopathies (9 male, 1 female; 68.2 ± 7.3 years). Both radiotracers were injected simultaneously and cardiac imaging was performed at 3.5 h after injection followed by brain imaging at 4 h after injection using standard protocols for MIBG-scintigraphy and DaT-SPECT. Additionally, five patients of the dual tracer protocol group received brain FDG-PET after DaT and MIBG imaging.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Single tracer imaging confirmed no relevant uptake of [¹²³I]ioflupane in the heart or [¹²³I]MIBG in the brain. Six out of the ten dual tracer protocol patients (PD or multiple system atrophy with Parkinsonian phenotype (MSA-P)) showed a significantly reduced DaT-SPECT binding (z-score &lt; -2) in at least one hemisphere (mean putaminal z-score -4.01 ± 1.39) while seven patients had a pathological heart-to-mediastinum ratio in the MIBG scan (mean H/M-ratio: 1.12 ± 0.08). Both DaT and MIBG scans could visually be interpreted without any signs of image artifacts or decrease in imaging quality and also quantitatively did not reveal significant differences to the single tracer scans. FDG-PET brain scans of the triple tracer protocol patients also showed no relevant interference in regard to image quality as well was generation of surface projections and z-scores.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>A single day protocol for DaT-SPECT, MIBG, and FDG-PET facilitates biomarker assessments needed for efficient biological characterization of Parkinsonian syndromes according to the SyNeurGe criteria.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"23 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143589625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}